Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 905-913

  Hope, William W ^a   Kaibara, Atsunori ^b   Roy, Michael ^b,e   Arrieta, Antonio ^c   Azie, Nkechi ^b   Kovanda, Laura L ^b   Benjamin, Daniel K ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ADOLESCENT; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; CANDIDIASIS; CHILD; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANDIDIASIS; HUMAN; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE; CANDIDIASIS, INVASIVE; CONTROLLED STUDY; FEMALE; INFANT; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTIFUNGAL AGENTS; CANDIDIASIS; CANDIDIASIS, INVASIVE; CHILD; CHILD, PRESCHOOL; ECHINOCANDINS; FEMALE; HUMANS; INFANT; LIPOPEPTIDES; MALE;

EID: 84921895829     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03736-14     Document Type: Article

References (19)

1. Astellas Pharma GmbH. 2008. Mycamine: summary of product characteristics. Astellas Pharma GmbH, Munich, Germany.
2. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45:883-893. http://dx.doi .org/10.1086/520980.
3. Astellas Pharma GmbH. 2013. Mycamine (micafungin sodium) package insert. Astellas Pharma GmbH, Munich, Germany.
4. Heresi GP, Gerstmann DR, Reed MD, van den Anker JN, Blumer JL, Kovanda L, Keirns JJ, Buell DN, Kearns GL. 2006. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 25:1110-1115. http://dx.doi.org/10.1097/01.inf .0000245103.07614.e1.
5. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DN, Walsh TJ. 2005. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 49:3317-3324. http://dx .doi.org/10.1128/AAC.49.8.3317-3324.2005.
6. Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ. 2007. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 51:3714-3719. http://dx.doi.org/10.1128/AAC.00398-07.
7. Hope WW, Smith PB, Arrieta A, Buell DN, Roy M, Kaibara A, Walsh TJ, Cohen-Wolkowiez M, Benjamin DK, Jr. 2010. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 54:2633-2637. http://dx.doi.org/10.1128/AAC.01679-09.
8. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ. 2004. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407-1416. http://dx.doi .org/10.1086/422312.
9. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised dou-ble-blind trial. Lancet 369:1519-1527. http://dx.doi.org/10.1016/S0140 -6736(07)60605-9.
10. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF. 2006. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53:337-349. http://dx.doi.org/10.1016/j.jinf.2006.03.003.
11. Lestner JM, Smith PB, Cohen-Wolkowiez M, Benjamin DK, Jr, Hope WW. 2013. Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. Br J Clin Pharmacol 75:1381-1395. http://dx.doi.org/10.1111/bcp.12025.
12. Benjamin DK, Jr, Deville JG, Azie N, Kovanda L, Roy M, Wu C, Arrieta A. 2013. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis. Pediatr Infect Dis J 32:e419-e425. http://dx.doi.org/10.1097/INF.0b013e31829efd14.
13. Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, Konja J, Diekmann-Berndt H, Koblinger S, Groll AH, Arrieta A. 2008. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 27:820-826. http://dx.doi.org/10 .1097/INF.0b013e31817275e6.
14. Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 60:329-331. http://dx.doi.org/10.1016/j.diagmicrobio.2007.09.018.
15. Benjamin DK, Jr, Smith PB, Arrieta A, Castro L, Sánchez PJ, Kaufman D, Arnold LJ, Kovanda LL, Sawamoto T, Buell DN, Hope WW, Walsh TJ. 2010. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 87:93-99. http://dx.doi.org/10.1038 /clpt.2009.200.
16. Smith PB, Walsh TJ, Hope W, Arrieta A, Takada A, Kovanda LL, Kearns GL, Kaufman D, Sawamoto T, Buell DN, Benjamin DK, Jr. 2009. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 28:412-415. http://dx.doi.org/10.1097/INF .0b013e3181910e2d.
17. Benjamin DK, Jr, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS. 2006. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 296:1266-1273. http://dx.doi .org/10.1001/jama.296.10.1266.
18. Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE, Cotton MP, Bacher J, Keirns JJ, Buell D, Heresi G, Benjamin DK, Jr, Groll AH, Drusano GL, Walsh TJ. 2008. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 197:163-171. http://dx.doi.org/10.1086/524063.
19. Hope WW, Howard SJ, Felton TW. 2012. Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions. Mycoses 55:33-38. http://dx.doi.org/10.1111/j.1439-0507 .2011.02114.x.